Repligen (RGEN)
(Delayed Data from NSDQ)
$115.88 USD
-0.62 (-0.53%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $115.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RGEN 115.88 -0.62(-0.53%)
Will RGEN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RGEN
Repligen (RGEN) Lags Q2 Earnings Estimates
Here's Why Repligen (RGEN) is a Strong Growth Stock
RGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Do Options Traders Know Something About Repligen (RGEN) Stock We Don't?
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
QGEN or RGEN: Which Is the Better Value Stock Right Now?
Other News for RGEN
Repligen Stock Outlook: Risk Skewed To The Downside Through 2026
Repligen partners with Novasign to use ML in filtration systems
Repligen (RGEN) Partners with Novasign to Enhance Filtration Systems
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing ...
Repligen announces strategic partnership with Novasign